GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alamar Biosciences, Inc. Common Stock ALMR · USD

US listing · 🇺🇸 United States

Compare

31.84

+13.51%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alamar Biosciences, Inc. Common Stock

Its shares trade under the ticker ALMR. It has been listed since 17 April 2026. In the fiscal year to 31 December 2025, it reported revenue of $74.2m and a net loss of $29.8m. At that date it held total assets of $140.0m and shareholders' equity of −$159.0m.

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
17 Apr 2026
Head office
47071 BAYSIDE PARKWAY, FREMONT, CA, 94538
Incorporated in
DE
Classification
Laboratory Analytical Instruments
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Alamar Biosciences develops NULISA technology for proteomic liquid biopsy detection.
  • The ARGO high throughput System supports ultra-high sensitivity and multiplexed analysis.
  • Alamar serves global research institutions and biopharmaceutical companies in key markets.

Weaknesses

  • Alamar operates in the United States and rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally.
  • The company was incorporated in 2018 and is based in Fremont, California.
  • Alamar Biosciences has a listing date of 17 April 2026.

Opportunities

  • Alamar Biosciences targets immunology, neurology, and oncology research areas for growth.
  • The proteomics platform can expand into new disease detection applications.
  • Alamar's instruments and consumables are sold to global research institutions.

Threats

  • Alamar Biosciences faces competition in the proteomics market.
  • The company's technology may face regulatory challenges in international markets.
  • Alamar's instruments require high precision and may have limited adoption.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.